Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 40, 2015, Pages 12480-12485

  Zhang, Meili ^a,b   Griner, Lesley A Mathews ^c   Ju, Wei ^a   Duveau, Damien Y ^c   Guha, Rajarshi ^c   Petrus, Michael N ^a   Wen, Bernard ^a   Maeda, Michiyuki ^d   Shinn, Paul ^c   Ferrer, Marc ^c   Conlon, Kevin D ^a   Bamford, Richard N ^e   O'Shea, John J ^f   Thomas, Craig J ^c   Waldmann, Thomas A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d KYOTO UNIVERSITY   (Japan)

^e NONE   (United States)

^f NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Adult t cell leukemia|janus kinase; Ruxolitinib|navitoclax

Indexed keywords

CASPASE 3; CASPASE 7; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 9; NAVITOCLAX; PROTEIN BCL XL; RUXOLITINIB; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; IL2RG PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR GAMMA; JANUS KINASE; PROTEIN BCL X; PYRAZOLE DERIVATIVE; STAT PROTEIN; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LEUKEMIA CELL LINE; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PARACRINE SIGNALING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T CELL LEUKEMIA; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CULTURE; DEFICIENCY; DRUG EFFECTS; DRUG SCREENING; FEMALE; FLOW CYTOMETRY; GENETICS; KNOCKOUT MOUSE; LEUKEMIA-LYMPHOMA, ADULT T-CELL; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; INTERLEUKIN-2; JANUS KINASES; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; PYRAZOLES; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84943251142     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1516208112     Document Type: Article

References (36)

1. Vainchenker W, Constantinescu SN (2013) JAK/STAT signaling in hematological malignancies. Oncogene 32(21):2601-2613.
2. Chen E, Staudt LM, Green AR (2012) Janus kinase deregulation in leukemia and lymphoma. Immunity 36(4):529-541.
3. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H (1977) Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood 50(3):481-492.
4. Shimoyama M (1991) Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 79(3):428-437.
5. Yamagishi M, Watanabe T (2012) Molecular hallmarks of adult T cell leukemia. Front Microbiol 3:334.
6. Nicot C, Mahieux R, Takemoto S, Franchini G (2000) Bcl-X(L) is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. Blood 96(1):275-281.
7. Tendler CL, et al. (1990) Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: Pathogenic implications and a rationale for immunotherapy. Proc Natl Acad Sci USA 87(13):5218-5222.
8. Waldmann TA (2006) The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat Rev Immunol 6(8):595-601.
9. Chen J, et al. (2008) Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. Blood 111(10):5163-5172.
10. Chen J, et al. (2010) Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia. Blood 116(26):5948-5956.
11. Ju W, et al. (2011) CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood 117(6):1938-1946.
12. Mathews Griner LA, et al. (2014) High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA 111(6):2349-2354.
13. Gozgit JM, et al. (2008) Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. JBiolChem283(47):32334-32343.
14. Diaz T, et al. (2011) Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis. PLoS One 6(4): e18856.
15. Harrison C, et al. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787-798.
16. Vaddi K, Sarlis NJ, Gupta V (2012) Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. Expert Opin Pharmacother 13(16):2397-2407.
17. Verstovsek S, et al. (2014) A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 120(4):513-520.
18. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 29(11):1039-1045.
19. Li F, Zhao C, Wang L (2014) Molecular-targeted agents combination therapy for cancer: Developments and potentials. Int J Cancer 134(6):1257-1269.
20. Will B, et al. (2010) Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood 115(14):2901-2909.
21. Waibel M, et al. (2013) Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Reports 5(4):1047-1059.
22. Souers AJ, et al. (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19(2):202-208.
23. Lessene G, et al. (2013) Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol 9(6):390-397.
24. Youle RJ, Strasser A (2008) The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9(1):47-59.
25. Walensky LD (2012) From mitochondrial biology to magic bullet: Navitoclax disarms BCL-2 in chronic lymphocytic leukemia. J Clin Oncol 30(5):554-557.
26. Czabotar PE, Lessene G, Strasser A, Adams JM (2014) Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. Nat Rev Mol Cell Biol 15(1): 49-63.
27. Han J, Goldstein LA, Hou W, Gastman BR, Rabinowich H (2010) Regulation of mitochondrial apoptotic events by p53-mediated disruption of complexes between antiapoptotic Bcl-2 members and Bim. J Biol Chem 285(29):22473-22483.
28. Weng C, Li Y, Xu D, Shi Y, Tang H (2005) Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem 280(11):10491-10500.
29. Gill PS, et al. (1995) Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 332(26):1744-1748.
30. Hermine O, et al. (1995) Brief report: Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 332(26):1749-1751.
31. Berkowitz JL, et al. (2014) Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clin Immunol 155(2):176-187.
32. Yamamoto K, et al. (2010) Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28(9):1591-1598.
33. Ishida T, et al. (2012) Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study. J Clin Oncol 30(8):837-842.
34. Marçais A, Suarez F, Sibon D, Bazarbachi A, Hermine O (2012) Clinical trials of adult T-cell leukaemia/lymphoma treatment. Leukemia Res Treat 2012:932175.
35. Hishizawa M, et al. (2010) Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: A nationwide retrospective study. Blood 116(8):1369-1376.
36. Chen Q, Lu Z, Jin Y, Wu Y, Pan J (2010) Triptolide inhibits Jak2 transcription and induces apoptosis in human myeloproliferative disorder cells bearing Jak2V617F through caspase-3-mediated cleavage of Mcl-1. Cancer Lett 291(2):246-255.